OncoTherapy Science (4564) AI Stock Analysis

• Market Cap: ¥8.83B
• Dividend Yield: N/A
• Average Volume (3M): 10.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: 22.93%
• EPS Growth: 47.73%
• Country: JP
• Employees: 54
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -3.16
• Shares Outstanding: 304,643,700
• 10 Day Avg. Volume: 8,925,550
• 30 Day Avg. Volume: 10,078,780
• PEG Ratio: -0.40
• Price to Book (P/B): 10.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥22.40
• Price Target Upside: -17.03% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ¥29.00 ▲(7.41%Upside)

The overall stock score for OncoTherapy Science is primarily impacted by its financial performance, which reflects significant challenges typical of high-risk biotech companies. While technical analysis indicates some positive price momentum, the poor valuation metrics due to negative earnings weigh heavily on the score.

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science (4564) is a biotechnology company based in Japan that focuses on the research and development of novel cancer therapies. The company is primarily involved in the discovery and development of cancer-targeted drugs, including therapeutic cancer vaccines, monoclonal antibodies, and small molecule drugs. OncoTherapy Science aims to address unmet medical needs in oncology through innovative treatment options.

How the Company Makes Money

OncoTherapy Science generates revenue through various streams, including licensing agreements, research and development collaborations, and potential product sales. The company often partners with pharmaceutical and biotechnology firms to co-develop and commercialize its therapeutic candidates, receiving milestone payments and royalties. Additionally, OncoTherapy Science may secure government and private grants to fund its research initiatives, further supporting its financial sustainability.

OncoTherapy Science Financial Statement Overview

Summary

OncoTherapy Science faces significant financial challenges, with persistent losses and cash flow issues. The income statement indicates operational inefficiencies and erratic revenue growth. The balance sheet shows a moderate debt-to-equity ratio but declining assets, while the cash flow statements reveal negative cash flows, posing liquidity risks. These factors result in a low financial performance score.

Income Statement

The company has experienced significant challenges in profitability, with consistently negative net and gross profit margins. Revenue growth is erratic, with fluctuations in revenue suggesting instability. EBIT and EBITDA margins have been consistently negative, indicating operational inefficiencies. Overall, the income statement reflects a struggling financial performance, typical in high-risk biotech ventures.

Balance Sheet

The balance sheet shows a relatively high equity ratio, supported by substantial stockholders' equity compared to total assets. However, the company carries significant liabilities, resulting in a moderate debt-to-equity ratio. The consistent decline in total assets and stockholders' equity over the years indicates potential risk. The company's ability to manage liabilities is crucial, given its negative equity growth trend.

Cash Flow

The cash flow statements reveal persistent negative free cash flow and operating cash flow, which are concerning for future liquidity. The company has relied heavily on financing activities to sustain operations, indicating potential challenges in sustaining cash flows from core operations. There is a lack of positive cash flow generation, which poses a risk to financial stability.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	750.05M	610.12M	1.13B	1.15B	332.48M
Gross Profit	-12.76M	-177.72M	41.69M	113.91M	19.54M
EBITDA	-811.92M	-1.29B	-1.09B	-2.04B	-1.59B
Net Income	-815.28M	-1.29B	-1.12B	-2.57B	-1.56B
Balance Sheet
Total Assets	1.16B	867.27M	1.51B	2.69B	3.37B
Cash, Cash Equivalents and Short-Term Investments	833.88M	527.66M	1.12B	1.84B	2.90B
Total Debt	51.07M	106.85M	0.00	0.00	0.00
Total Liabilities	426.09M	513.61M	656.27M	704.97M	291.28M
Stockholders Equity	729.11M	353.67M	855.17M	1.98B	3.08B
Cash Flow
Free Cash Flow	-815.30M	-1.23B	-800.29M	-2.53B	-1.81B
Operating Cash Flow	-815.02M	-1.23B	-794.90M	-2.07B	-1.76B
Investing Cash Flow	-279.00K	-33.35M	-20.32M	-467.93M	-52.23M
Financing Cash Flow	1.12B	671.37M	95.95M	1.48B	0.00

OncoTherapy Science Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 27.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Positive. The current price of 27 is below the 20-day moving average (MA) of 29.00, above the 50-day MA of 25.22, and below the 200-day MA of 27.27, indicating a neutral trend. The MACD of 1.02 indicates Positive momentum. The RSI at 54.68 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4564.

OncoTherapy Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.60B	0.11	-62.95%	2.07%	16.16%	0.31%
4593	51 Neutral	¥78.04B	―		―	374.19%	35.53%
4583	48 Neutral	¥10.00B	―		―	14.41%	27.42%
4588	48 Neutral	¥15.30B	―		―	11.93%	15.04%
4564	47 Neutral	¥8.83B	―	-148.36%	―	22.93%	47.73%
4881	38 Underperform	¥4.46B	―		―	1056.04%	21.63%
4598	28 Underperform	¥8.64B	―		―	―	-11.46%